Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Breakthrough” Therapies: Pharmacyclics Gains More Access, Certainty For Ibrutinib

Executive Summary

Company Chief Medical Officer Kunkel says FDA has talked about manufacturing and trial design for its breakthrough designee much earlier than would be expected with a typical application.

You may also be interested in...



Breakthrough Designation Is A Two-Way Street, FDA Cautions Sponsors

Sponsors of would-be breakthrough therapies need to move as quickly as FDA is acting, from responding to emails to ramping up manufacturing so they can start trials earlier.

‘Breakthrough’ Therapies: Information Requests A Sign Of Workload Problem?

FDA on average sent about 20 more information requests during breakthrough product reviews than others in the Program, according to interim assessment of the PDUFA V review system. Assessment could support higher funding for breakthrough program in next user fee round.

Aisling, Clarus Make Huge Bets On Royalties

When was the last time a life science venture firm spent close to $50 million all in one go? It doesn't happen often, but Aisling Capital and Clarus Ventures have each put up $48.5 million for a tiny slice of sales royalties from ibrutinib, a promising cancer drug that could receive FDA approval this calendar year or early next.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel